Survival and CTC data from the abiraterone acterate pivotal trial

As we have previously reported, the latest analysis of survival data from the pivotal Phase III trial of abiraterone acetate + predisone has shown a slight improvement in the survival benefit for patients treated with abiraterone (Zytiga™). … READ MORE …

The Monday news update: March 2, 2009

New reports today address:

  • Positive surgical margins: RALP vs. RRP
  • Circulating tumor cells levels and survival of castration-resistant prostate cancer patients
  • Patient preference and management of post-surgical incontinence … READ MORE …